| Autor: |
J Fowler, Sarah C. Gilbert, M Pace, T Tipton, M Bittaye, Sarah Fidler, T Tipoe, R Makinson, Panagiota Zacharopoulou, S Serrano, C Petersen, Federica Cappuccini, Andrew J. Pollard, Matthew Jones, H Fok, S Broadhead, Alagaratnam J, S Adele, Yama F Mujadidi, John Frater, Julie Fox, Miles W. Carroll, Anele Waters, E Barnes, H Sanders, Katie J. Ewer, M A Ansari, N Robinson, P Goulder, Emma Plested, M N Ramasamy, S Rhead, L Parolini, Wanwisa Dejnirattisai, Susanna Dunachie, S Longet, T Rajeswaran, B Jackson, D Jenkin, Parvinder K. Aley, P M Folegatti, Alissa Goodman, A Mazzella, A Bara, H Stockmann, M Mathew, P Cinardo, Alan Winston, Harriet R. Brown, Hannah Robinson, Katrina M Pollock, Gavin R. Screaton, Laura Godfrey, Ane Ogbe, Anthony Brown, Hill Avs., N G Marchevsky, Paul Klenerman, Teresa Lambe |
| Rok vydání: |
2021 |
| Předmět: |
|
| Popis: |
Duration of protection from SARS-CoV-2 infection in people with HIV (PWH) following vaccination is unclear. In a sub-study of the phase 2/3 the COV002 trial (NCT04400838), 54 HIV positive male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells >350 cells/ul) received two doses of ChAdOx1 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and MesoScale Discovery (MSD)), neutralisation, ACE-2 inhibition, gamma interferon ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that 6 months after vaccination the majority of measurable immune responses were greater than pre-vaccination baseline, but with evidence of a decline in both humoral and cell mediated immunity. There was, however, no significant difference compared to a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although were lower than wild type. Pre-existing cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater post-vaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the on-going policy to vaccinate PWH against SARS-CoV-2, and underpin the need for long-term monitoring of responses after vaccination. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
